REG - GENinCode PLC - Proposed independent directorate appointment

GenincodeAnnouncement

21/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220121:nRSU1605Za&default-theme=true

RNS Number : 1605Z  GENinCode PLC  21 January 2022

21 January 2022

GENinCode Plc

("GENinCode" or the "Company")

 

Proposed independent directorate appointment

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces its intention to
appoint Professor Huon Gray CBE, to the Board as an independent non-executive
director.

 

Huon has 30 years' experience practising as a consultant cardiologist for the
NHS and private sector, with particular experience in cardiovascular risk
assessment and interventional cardiology. Huon served as the National Clinical
Director for Heart Disease in the Department of Health and then NHS England
from 2012-2019, advising government, all party parliamentary groups, the NHS
and NICE on healthcare delivery and reform. He is a former President of the
British Cardiac Society (now the British Cardiovascular Society) and was
previously Chair of the International Committee of the American College of
Cardiology.

 

In 2018, Huon was awarded the honour of Master of the American College of
Cardiology, the only recipient outside of the US, and the Mackenzie Medal by
the British Cardiovascular Society in 2014 in recognition of his services to
British cardiology. In 2019, he was made a CBE for his services to cardiology.

 

Huon's exposure to the US healthcare system through his work with the American
College of Cardiology over 15 years, in roles such as Trustee and Chair of its
Governance Committee, will support the Company as it targets the US as one of
its primary markets. Additionally, during Huon's tenure at NHS England, he
acted as a liaison with industry and Academic Health Science Networks, helping
deliver healthcare in the NHS through encouraging the adoption of innovation
and new technology.

 

Huon will be appointed to the board of GENinCode following finalisation of the
terms of his appointment and the completion of the necessary regulatory due
diligence in accordance with the AIM Rules.

 

In addition, GENinCode anticipates appointing an additional independent
non-executive director in the short-term. A suitably qualified US-based
candidate has been identified that is an experienced healthcare industry and
US FDA regulatory veteran and whom the Board believes will be very additive to
GENinCode's future.

 

Further announcements will be made at the appropriate time.

 

Bill Rhodes, Chair of GENinCode Plc, commented: "We are delighted to have Huon
join the Board, subject to completion of the necessary formalities. Huon has
extensive and expansive experience in clinical cardiology and through his
relationships globally, and particularly in the US and the UK, coupled with
his deep appreciation for the benefits both patients and practitioners will
gain from the use of our products, there is no question he will add tremendous
value to the Board, the Company and our shareholders."

 

Matthew Walls, CEO of GENinCode Plc, added: "Huon's background and vast
experience as a leading cardiologist in both the UK and the US will be
invaluable to the Company as we look towards commercialisation later in 2022.
Importantly, he shares our excitement about the potential of the Company's
portfolio of products to drastically improve the current standard of care
worldwide."

 

Professor Huon Gray CBE commented: "I am delighted to be asked to join the
Board of GENinCode at this important stage. Cardiovascular risk assessment in
the US and UK currently comprises a series of questions related to
conventional risk factors, with no genetic risk assessment. This is despite
family history being one of the most significant contributing risk factors to
an individual's likelihood of suffering from cardiovascular disease.
Consequently, the Company's portfolio of diagnostic products have significant
potential to improve the standard of care for millions who every year suffer
from cardiovascular disease."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                    Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short


 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                              Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, in the United States through
GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an
estimated 17.9 million lives each year. CVD is a group of disorders of the
heart and blood vessels and include coronary heart disease, cerebrovascular
disease, rheumatic heart disease and other conditions. More than four out of
five CVD deaths are due to heart attacks and strokes, and one third of these
deaths occur prematurely in people under 70 years of age.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Cessation of tobacco use, reduction of salt in the diet, eating more fruit and
vegetables, regular physical activity and avoiding harmful use of alcohol have
been shown to reduce the risk of cardiovascular disease. Health policies that
create conducive environments for making healthy choices affordable and
available are essential for motivating people to adopt and sustain healthy
behaviours.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas and is the single biggest area where the
NHS can save lives over the next 10 years. CVD is largely preventable, through
lifestyle changes and a combination of public health and NHS action on smoking
and tobacco addiction, obesity, tackling alcohol misuse and food
reformulation.

 

Genetic risk assessment can help early detection and treatment of CVD to help
patients live longer, healthier lives. Many people are still living with
undetected, high-risk conditions such as high blood pressure, raised
cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to
identify and diagnose people routinely knowing their 'ABC' (testing and
monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year
plan.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGZMRGZGZZM